Is there a treatment necessity for lipid disorders of uremic patients?

Blood Purif. 1985;3(1-3):42-51. doi: 10.1159/000169397.

Abstract

In the present review, the role of lipid disturbances is evaluated as a risk factor in the pathogenesis and the potential acceleration of atherosclerosis in uremic patients undergoing long-term hemodialysis. The alteration in high density lipoprotein composition with a decrease in high density lipoprotein cholesterol but a normal apoprotein AI content may have relevance to the atherogenetic process. Moreover, the accumulation of cholesterol-rich, very low density lipoproteins and intermediate density lipoproteins may play a major role in atherosclerosis since these degradation products of triglyceride-rich particles are considered as atherogenic. The hypothesis should be tested whether a correction of the abnormal catabolism of triglyceride-rich lipoproteins in uremic patients leads to a decrease in ischemic vascular events.

Publication types

  • Review

MeSH terms

  • Animals
  • Apolipoprotein A-I
  • Apolipoprotein A-II
  • Apolipoprotein C-III
  • Apolipoproteins A / blood
  • Apolipoproteins C / blood
  • Arteries / metabolism
  • Arteriosclerosis / blood
  • Arteriosclerosis / etiology
  • Calcium / metabolism
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Dogs
  • Female
  • Humans
  • In Vitro Techniques
  • Kidney Failure, Chronic / blood
  • Kidney Failure, Chronic / complications
  • Lipids / blood*
  • Lipoproteins, VLDL / blood
  • Male
  • Rabbits
  • Rats
  • Risk
  • Uremia / blood
  • Uremia / complications*

Substances

  • Apolipoprotein A-I
  • Apolipoprotein A-II
  • Apolipoprotein C-III
  • Apolipoproteins A
  • Apolipoproteins C
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Lipids
  • Lipoproteins, VLDL
  • Calcium